Clinical and Laboratory Biomarkers as Predictors of Severity in Pediatric Inflammatory Multisystem Syndrome-temporally Associated With SARS-CoV-2: Data From a Prospective Nationwide Surveillance Study in Switzerland

Pediatr Infect Dis J. 2024 Jul 1;43(7):675-681. doi: 10.1097/INF.0000000000004332. Epub 2024 Mar 20.

Abstract

Background: PIMS-TS (pediatric inflammatory multisystem syndrome-temporally associated with SARS-CoV-2) is a rare but serious condition in children following SARS-CoV-2 infection, characterized by a range of clinical symptoms with varying severity. Understanding risk factors for severe PIMS-TS is crucial for appropriate and timely intervention.

Objective: To identify factors associated with increased PIMS-TS severity in children.

Methods: In this nationwide prospective observational study, epidemiological and clinical data was collected from children <18 years of age with suspected or confirmed PIMS-TS from all 29 pediatric hospitals in Switzerland. Children were categorized into 3 groups according to admission to intensive care unit (ICU): non-ICU, ICU-moderate and ICU-severe, defined as requirement of invasive ventilation and/or inotropic support.

Results: A total of 204 children were included; 99 (49%) were categorized as non-ICU, 50 (25%) as ICU-moderate and 55 (27%) as ICU-severe. In ICU-severe cases, respiratory and neurological symptoms were more frequent compared with non-ICU cases: 72% versus 47%, P < 0.001 and 66% versus 41%, P = 0.001, respectively. Compared with the non-ICU group, children in the ICU-severe group had lower lymphocyte counts, higher neutrophil-lymphocyte ratios, lower platelet counts, as well as higher C-reactive protein, N-terminal pro-B-type natriuretic peptide, troponin T and creatinine levels at admission. Lymphopenia and elevated troponin T levels at admission were associated with an increased risk of being in the ICU-severe group.

Conclusion: The severity of PIMS-TS may be predicted using clinical symptoms and laboratory biomarkers, which help clinicians in decision-making and management of patients.

Publication types

  • Observational Study

MeSH terms

  • Adolescent
  • Biomarkers* / blood
  • COVID-19* / blood
  • COVID-19* / complications
  • COVID-19* / diagnosis
  • COVID-19* / epidemiology
  • Child
  • Child, Preschool
  • Female
  • Humans
  • Infant
  • Male
  • Prospective Studies
  • Risk Factors
  • SARS-CoV-2*
  • Severity of Illness Index*
  • Switzerland / epidemiology
  • Systemic Inflammatory Response Syndrome* / blood
  • Systemic Inflammatory Response Syndrome* / diagnosis
  • Systemic Inflammatory Response Syndrome* / epidemiology

Substances

  • Biomarkers

Supplementary concepts

  • pediatric multisystem inflammatory disease, COVID-19 related